ACTI.ST Active Biotech AB (publ)
STOHealthcareAs of 2026-06-03 09:50
Valuation
View DetailsP/E (TTM)
-433.01
PEG
—
P/B
318.34
P/S
0.00
EV/EBITDA
-213.69
DCF Value
—
FCF Yield
-0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-117.8%
ROA
-59.6%
ROIC
-74.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.4M | $-0.00 |
| Q4 2025 | $0.00 | $-9.1M | $-0.01 |
| Q3 2025 | $0.00 | $-6.0M | $-0.00 |
| Q2 2025 | $0.00 | $-11.2M | $-0.01 |
Listing Info
Market
US
Exchange
STO
Currency
USD
Sector
Healthcare
Industry
Biotechnology
Country
SE
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.